Lexington Biosciences Inc. (LXGTF)

[77Port]

I wrote the following paragraph on Oct 5: "I recall seeing a timeline that was longer in length that what is now occurring and it's possible LEX was forced to move earlier than planned due to market forces. They would have to get the patent or else risk losing it since the science of what they are doing was no longer secret. I don't think any of this is significantly unusual."

And so the plot thickens as the competitors appear coming around the bend. In fact, this might be a classic competitive race which capitalism thrives upon.

Sabertooth0071 looked through Endothelix and Vendys II. While speculative, with this new site, Endothelix, seemingly springing to full-size overnight, it might have been the all-nighter, last ditch attempt by parent company Itamar Medical, specializing in sleep disorders, to keep themselves in the race.

Endothelix website mentioning the Endothelix Vendys II and the Endopat with name of parent company: https://www.endothelix.com/physicians/competitive-advantages/

Itamar Medical: https://www.itamar-medical.com/

Itamar Medical explanation: https://www.itamar-medical.com/wp-content/uploads/2016/08/company-profile-august2016.pdf

Itamar Medical seems to have been in this space for awhile. And it's possible, maybe even likely, that it's LEX who is jumping the shark. Who knows? Itamar Medical is also a penny stock which has had trouble growing.

Itamar Medical stock price: https://seekingalpha.com/symbol/ITMMF?s=itmmf

And here's a crazy thought. If any of this is accurate, then it's a good sign for LEX that Itamar Medical is scared. Even though today's news has scared some of us, too.

Itamar Medical is no joke, an Israeli healthcare company involved in healthcare across Europe. They see sleep apnea as a key to many disorders, including cardiac. Site says,: "Itamar Medical is dedicated to the research, development and commercialization of a wide range of medical products based on the PAT (Peripheral Arterial Tone) Technology in order to improve the quality of healthcare."

This is why this is never a sure thing. Perhaps people from Itamar and LEX knew each other at Berkeley U or Berkeley Labs? Who knows? But ideas sometimes end up racing to the finish line. And as I said on Oct 5, as well as in this first paragraph, LEX seemed to know the heat was on to speed up their initial timeline. The fact that Itamar Medical released Endothelix overnight, as it seems to have done, means that they or either scared or else they are trying to be the first to introduce non-invasive endothelial function into the world of heart health. Bottom line: I agree with Sabertooth that LEX is better tech and better research, but now it's truly clear that LEX can't slow down.

While Marketbuy's worry of running out of money prior to getting the trials and FDA approval finished is, no doubt, all true, if this race is as important as it seems to be, there would have to be bigger pockets willing to help (for a price, of course). Seems like LEX has been trying to do this on their own to maximize future profits. Let's hope they succeed. But if they can't make it all the way on their own, then there might need to be some dilution to get all the way home.

This is what penny stocks are about: action. And action is both exciting and terrifying. It's a roller coaster so either we are brought to a calm halt or else we might be thrown off the rails at the top with our pockets empty. I vote for the former over the latter but I have absolutely no power over what happens. Here is where the red/black bet on the roulette table seems like an apt analogy, but I continue to believe holding is the best choice for me.